Navigation Links
Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Date:11/27/2007

ate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540 and PS178990, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such fil
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmacopeia Announces Senior Additions to Management Team
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. GlaxoSmithKline Responds to JAMA Articles
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
6. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
7. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
8. GlaxoSmithKline Aids California Fire Relief Efforts
9. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Quintessa Medical ... Kybella is a nonsurgical treatment designed specifically for the elimination of excess ... of the first locations in the state of Wisconsin to offer this innovative treatment. ...
(Date:7/30/2015)... ... 30, 2015 , ... The Tisch Cancer Institute at Icahn ... Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai ... elite group of 69 cancer institutions nationwide that have earned this designation, which ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks ... in his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, ... message: “If we take responsibility for ourselves, we can create better realities.” His book ...
(Date:7/30/2015)... ... 30, 2015 , ... WellSpan Health in York, Pa., has ... claims for bariatric surgery that, despite complying with national and local coverage determinations, ... nurse auditor at WellSpan Health, tells Atlantic Information Services’ (AIS) Report on Medicare ...
(Date:7/30/2015)... ... ... weight, many people place a lot of focus on the different types of food that need ... another key component to successful weight gain is knowing when to eat so that ... Gainer gives three tips on when to eat to gain weight. , The first thing ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... a part of National Health Service (NHS) that offers support to ... has decided// to cut hundreds of jobs as part of a ... going on about the issue. But unions fear that as many ... set up eight years ago as a new approach to take ...
... that periodontal disease is not a desirable condition in ... the first time researchers from Case Western Reserve University ... and Gynecology at MetroHealth Medical Center in Cleveland have ... ,Their report, titles, "Transmission of an Uncultivated Bergeyella Strain ...
... India the Reserve Bank of India (RBI) is not allowing ... and the State Bank of India (SBI) // facing difficulties ... , The Comprehensive Economic Cooperation Agreement (CECA) that was ... The Monetary Authority of Singapore (MAS), or central bank, ...
... people who suffer whiplash injuries can recover soon with ... Quebec, Canada.// The Whiplash Management strategy is a big ... initiative being better cost economy and earlier resumption of ... target, better practices in management of patient care that ...
... with inherited retinal degeneration have hope of vision since ... light sensitive that were not before.// ,Zhuo-Hua ... colleagues have engineered this technology using a harmless virus, ... "inner retinal neurons" in a strain of mice with ...
... of Kaiser Permanente, overweight or obesity during one’s middle ... in life. ,'The study was presented during ... San Diego. ,The researchers from the Kaiser ... 9,000 people for a period of 30 years. ...
Cached Medicine News:Health News:Strained Economic Agreement Between Singapore And India 2Health News:There is light at the end of the blind tunnel: prosthetic retinal cells offer hope! 2
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... MONICA, Calif. , July 29, 2015  UBM ... the San Diego Marriott Marquis & Marina on September ... medical device industry. A highlight of the Business Development ... Financial Backing from Different Types of Investors, featuring ... & Johnson Development Corporation; Brent Ahrens , Partner, ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... NEW YORK, Jan. 11, 2011 WebMD Health Corp. (Nasdaq: ... private placement of $400 million aggregate principal amount of 2.50% ... of notes pursuant to the exercise in full of the ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will participate in the Arab Health Exhibition ... 2011 at the Dubai World Trade Centre in Dubai, ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Dehaier Medical Announces Participation in Arab Health 2011 2